{"generic":"Coagulation Factor IX Recombinant","drugs":["Benefix","Coagulation Factor IX Recombinant","Ixinity","Rixubis"],"mono":{"0":{"id":"928514-s-0","title":"Generic Names","mono":"Coagulation Factor IX Recombinant"},"1":{"id":"928514-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928514-s-1-4","title":"Adult Dosing","mono":"<ul><li>dosing of recombinant coagulation factor IX may be different from that of plasma-derived factor IX products; may require dosage adjustment as much as 2 times the initial calculated dose to achieve the intended rise in circulating factor IX activity<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Initial dose = body weight (kg) multiplied by desired factor IX increase (% of normal or international units\/dL) multiplied by reciprocal of observed recovery (international units\/kg per international units\/dL), IV<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Benefix(R) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (% or international units\/dL) multiplied by 1.2 international units\/kg per international units\/dL, IV<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Ixinity(R) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (% or international units\/dL) multiplied by 1.02 dL\/kg, IV<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Rixubis(TM) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (% or international units\/dL) multiplied by 1.1 dL\/kg, IV<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Benefix(R); Rixubis(TM) mild hemorrhage, 20% to 30% of normal factor IX level or 20 to 30 international units\/dL factor IX activity required IV every 12 to 24 hours  for 1 to 2 days (Benefix(R)), or for at least 1 day, until healing is achieved (Rixubis(TM))<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Benefix(R); Rixubis(TM) moderate hemorrhage, 25% to 50% of normal factor IX level or 25 to 50 international units\/dL activity required IV every 12 to 24 hours for 2 to 7 days  until bleeding stops and healing achieved<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Benefix(R); Rixubis(TM) major hemorrhage, 50% to 100% of normal factor IX level or 50 to 100 international units\/dL activity required IV every 12 to 24 hours for 7 to 10 days  until bleeding stops and healing achieved<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Ixinity(R) minor hemorrhage, 30% to 60% of normal factor IX level or 30 to 60 international units\/dL factor IX activity required IV every 24 hours for 1 to 3 days, until healing is achieved<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Ixinity(R) moderate hemorrhage, 40% to 60% of normal factor IX level or 40 to 60 international units\/dL factor IX activity required IV every 24 hours for 2 to 7 days, until healing is achieved<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Ixinity(R) major or life-threatening hemorrhage, 60% to 100% of normal factor IX level or 60 to 100 international units\/dL factor IX activity required IV every 12 to 24 hours for 2 to 14 days, until healing is achieved<\/li><li><b>Hemophilia B - Hemorrhage, Routine prophylaxis:<\/b> (Rixubis(TM), previously treated patients) 40 to 60 international units\/kg IV, twice a week; titrate as necessary for individual age, bleeding pattern, and physical activity<\/li><li><b>Hemophilia B - Perioperative care:<\/b> Initial dose = body weight (kg) multiplied by desired factor IX increase (% of normal or international units\/dL) multiplied by reciprocal of observed recovery (international units\/kg per international units\/dL), IV<\/li><li><b>Hemophilia B - Perioperative care:<\/b> Benefix(R) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (% or international units\/dL) multiplied by 1.2 international units\/kg per international units\/dL, IV<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Benefix(R), mild hemorrhage) 20% to 30% of normal factor IX level or 20 to 30 international units\/dL factor IX activity required IV every 12 to 24 hours for 1 to 2 days<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Benefix(R), moderate hemorrhage) 25% to 50% of normal factor IX level or 25 to 50 international units\/dL activity required IV every 12 to 24 hours for 2 to 7 days<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Benefix(R), major hemorrhage) 50% to 100% of normal factor IX level or 50 to 100 international units\/dL activity required IV every 12 to 24 hours for 7 to 10 days<\/li><li><b>Hemophilia B - Perioperative care:<\/b> Ixinity(R) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (% or international units\/dL) multiplied by 1.02 dL\/kg, IV<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Ixinity(R), minor surgery) Pre-op: 50 to 80 international units\/dL or 50% to 80% of normal factor IX level required IV; Post-op: 30 to 80 international units\/dL or 30% to 80% of normal factor IX level required IV every 24 hours for 1 to 5 days, depending on procedure<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Ixinity(R), major surgery) Pre-op: 60 to 80 international units\/dL or 60% to 80% of normal factor IX level required IV; Post-op: Administer every 8 to 24 hours IV based on desired peak level; 40 to 60 international units\/dL or 40% to 60% of normal factor IX level for 1 to 3 days; 30 to 50 international units\/dL or 30% to 50% of normal factor IX level for 4 to 6 days; 20 to 40 international units\/dL or 20% to 40% of normal factor IX level for 7 to 14 days<\/li><li><b>Hemophilia B - Perioperative care:<\/b> Rixubis(TM) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (% or international units\/dL) multiplied by 1.1 dL\/kg, IV<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Rixubis(TM), minor surgery) 30 to 60 international units\/dL or 30% to 60% of normal factor IX level required IV every 24 hours for 1 or more days until healing is achieved<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Rixubis(TM), major surgery) 80 to 100 international units\/dL or 80 to 100% of normal factor IX level required IV every 8 to 24 hours for 7 to 10 days until bleeding stops and healing is achieved<\/li><\/ul>"},"1":{"id":"928514-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>dosing of recombinant coagulation factor IX may be different from that of plasma-derived factor IX products; may require dosage adjustment as much as 2 times the initial calculated dose to achieve the intended rise in circulating factor IX activity<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Initial dose = body weight (kg) multiplied by desired factor IX increase (% of normal or international units\/dL) multiplied by reciprocal of observed recovery (international units\/kg per international units\/dL), IV<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> (Benefix(R), younger than 15 years) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (%) multiplied by 1.4 international units\/kg, IV<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> (Benefix(R), 15 years or older) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (% or international units\/dL) multiplied by 1.2 international units\/kg per international units\/dL, IV<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> (Ixinity(R), 12 years and older) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (% or international units\/dL) multiplied by 1.02 dL\/kg, IV<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> (Rixubis(TM), younger than 12 years) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (%) multiplied by 1.4 international units\/kg, IV<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> (Rixubis(TM), 12 years or older) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (% or international units\/dL) multiplied by 1.1 dL\/kg, IV<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Benefix(R); Rixubis(TM) mild hemorrhage, 20% to 30% of normal factor IX level or 20 to 30 international units\/dL factor IX activity required IV every 12 to 24 hours  for 1 to 2 days (Benefix(R)), or for at least 1 day, until healing is achieved (Rixubis(TM))<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Benefix(R); Rixubis(TM) moderate hemorrhage, 25% to 50% of normal factor IX level or 25 to 50 international units\/dL activity required IV every 12 to 24 hours for 2 to 7 days  until bleeding stops and healing achieved<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> Benefix(R); Rixubis(TM) major hemorrhage, 50% to 100% of normal factor IX level or 50 to 100 international units\/dL activity required IV every 12 to 24 hours for 7 to 10 days  until bleeding stops and healing achieved<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> (Ixinity(R), 12 years and older) minor hemorrhage, 30% to 60% of normal factor IX level or 30 to 60 international units\/dL factor IX activity required IV every 24 hours for 1 to 3 days, until healing is achieved<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> (Ixinity(R), 12 years and older) moderate hemorrhage, 40% to 60% of normal factor IX level or 40 to 60 international units\/dL factor IX activity required IV every 24 hours for 2 to 7 days, until healing is achieved<\/li><li><b>Hemophilia B - Hemorrhage:<\/b> (Ixinity(R), 12 years and older) major or life-threatening hemorrhage, 60% to 100% of normal factor IX level or 60 to 100 international units\/dL factor IX activity required IV every 12 to 24 hours for 2 to 14 days, until healing is achieved<\/li><li><b>Hemophilia B - Hemorrhage, Routine prophylaxis:<\/b> (Rixubis(TM), younger than 12 years, previously treated) 60 to 80 international units\/kg IV twice weekly; titrate as necessary for individual age, bleeding pattern, and physical activity<\/li><li><b>Hemophilia B - Hemorrhage, Routine prophylaxis:<\/b> (Rixubis(TM), 12 years or older, previously treated) 40 to 60 international units\/kg IV twice weekly; titrate as necessary for individual age, bleeding pattern, and physical activity<\/li><li><b>Hemophilia B - Perioperative care:<\/b> Initial dose = body weight (kg) multiplied by desired factor IX increase (% of normal or international units\/dL) multiplied by reciprocal of observed recovery (international units\/kg per international units\/dL), IV<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Benefix(R), younger than 15 years) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (% or international units\/dL) multiplied by 1.4 international units\/kg per international units\/dL, IV<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Benefix(R), 15 years or older) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (% or international units\/dL) multiplied by 1.2 international units\/kg per international units\/dL, IV<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Benefix(R), mild hemorrhage) 20% to 30% of normal factor IX level or 20 to 30 international units\/dL factor IX activity required IV every 12 to 24 hours for 1 to 2 days<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Benefix(R), moderate hemorrhage) 25% to 50% of normal factor IX level or 25 to 50 international units\/dL activity required IV every 12 to 24 hours for 2 to 7 days<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Benefix(R), major hemorrhage) 50% to 100% of normal factor IX level or 50 to 100 international units\/dL activity required IV every 12 to 24 hours for 7 to 10 days<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Ixinity(R), 12 years and older) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (% or international units\/dL) multiplied by 1.02 dL\/kg, IV<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Ixinity(R), minor surgery, 12 years and older) Pre-op: 50 to 80 international units\/dL or 50% to 80% of normal factor IX level required IV; Post-op: 30 to 80 international units\/dL or 30% to 80% of normal factor IX level required IV every 24 hours for 1 to 5 days, depending on procedure<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Ixinity(R), major surgery, 12 years and older) Pre-op: 60 to 80 international units\/dL or 60% to 80% of normal factor IX level required IV; Post-op: Administer every 8 to 24 hours IV based on desired peak level; 40 to 60 international units\/dL or 40% to 60% of normal factor IX level for 1 to 3 days; 30 to 50 international units\/dL or 30% to 50% of normal factor IX level for 4 to 6 days; 20 to 40 international units\/dL or 20% to 40% of normal factor IX level for 7 to 14 days<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Rixubis(TM), younger than 12 years) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (% or international units\/dL) multiplied by 1.4 dL\/kg, IV<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Rixubis(TM), 12 years or older) number of recombinant factor IX complex international units required = body weight (kg) multiplied by desired factor IX increase (% or international units\/dL) multiplied by 1.1 dL\/kg, IV<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Rixubis(TM), minor surgery) 30 to 60 international units\/dL or 30% to 60% of normal factor IX level required IV every 24 hours for 1 or more days until healing is achieved<\/li><li><b>Hemophilia B - Perioperative care:<\/b> (Rixubis(TM), major surgery) 80 to 100 international units\/dL or 80 to 100% of normal factor IX level required IV every 8 to 24 hours for 7 to 10 days until bleeding stops and healing is achieved<\/li><\/ul>"},"3":{"id":"928514-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Hemophilia B - Hemorrhage<\/li><li>Hemophilia B - Hemorrhage, Routine prophylaxis<\/li><li>Hemophilia B - Perioperative care<\/li><\/ul>"}}},"3":{"id":"928514-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928514-s-3-9","title":"Contraindications","mono":"<ul><li>disseminated intravascular coagulation (DIC)<\/li><li>fibrinolysis, signs of<\/li><li>hypersensitivity to coagulation factor IX recombinant, hamster protein, or any component of the product<\/li><\/ul>"},{"id":"928514-s-3-10","title":"Precautions","mono":"<ul><li>factor IX inhibitor development; increased risk of severe hypersensitivity reactions including anaphylaxis; monitoring recommended<\/li><li>fibrinolysis, peri- and postoperative signs; increased risk of thromboembolic events (eg, pulmonary embolism, venous thrombosis, arterial thrombosis); monitoring recommended<\/li><li>hamster protein component; hypersensitivity may develop<\/li><li>hepatic disease; increased risk of thromboembolic events (eg, pulmonary embolism, venous thrombosis, arterial thrombosis); monitoring recommended<\/li><li>hypersensitivity reactions, including anaphylaxis, have been reported; increased risk during first exposures in treatment-naive patients, particularly those with high-risk gene mutations; discontinue use if suspected<\/li><li>nephrotic syndrome has occurred following attempted immune tolerance induction with factor IX inhibitors<\/li><li>patients at high-risk for thrombotic events or disseminated intravascular coagulation (DIC); increased risk of thromboembolic events (eg, pulmonary embolism, venous thrombosis, arterial thrombosis); monitoring recommended<\/li><li>thromboembolic events (eg, pulmonary embolism, venous thrombosis, arterial thrombosis) have been reported with the use of factor X containing products; monitoring recommended<\/li><li>report suspected adverse reactions to the US Food and Drug administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"928514-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"928514-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"928514-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Immunologic:<\/b>Antibody development (21.2%)<\/li><li><b>Neurologic:<\/b>Headache (2.6%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Thromboembolic disorder<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Renal:<\/b>Nephrotic syndrome<\/li><\/ul>"},"6":{"id":"928514-s-6","title":"Drug Name Info","sub":{"0":{"id":"928514-s-6-17","title":"US Trade Names","mono":"<ul><li>Benefix<\/li><li>Rixubis<\/li><li>Ixinity<\/li><\/ul>"},"2":{"id":"928514-s-6-19","title":"Class","mono":"Antihemophilic Agent<br\/>"},"3":{"id":"928514-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928514-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928514-s-7","title":"Mechanism Of Action","mono":"All forms of factor IX achieve hemostasis through the same mechanism.  A complex of factor VII and tissue factor (via the extrinsic coagulation pathway) and factor XIa (via the intrinsic pathway) activate factor IX which, in combination with factor VIII, activates factor X. Through this pathway, prothrombin is converted to thrombin which, in turn, converts fibrinogen to fibrin clot. Coagulation factor IX, recombinant, is used to temporarily replace missing coagulation factor IX in patients with hemophilia B.<br\/>"},"8":{"id":"928514-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"928514-s-8-24","title":"Distribution","mono":"Vd: 178.6 mL\/kg <br\/>"},"3":{"id":"928514-s-8-26","title":"Excretion","mono":"Total body clearance: 6 mL\/(kg x hr) <br\/>"},"4":{"id":"928514-s-8-27","title":"Elimination Half Life","mono":"18.8 to 25.4 hours <br\/>"}}},"9":{"id":"928514-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>Allow the lyophilized powder and diluent to reach room temperature<\/li><li>Benefix(R), use double-ended needle to transfer provided diluent to single-dose vial; direct flow of diluent against side of vial<\/li><li>Benefix(R), let vial stand until contents are in solution and then swirl gently; do not shake; do not invert vial until ready to withdraw contents<\/li><li>Use as soon as possible (within 3 hours) after reconstitution; include storage time elapsed in a polyvinylchloride container; discard unused portion<\/li><li>Benefix(R), using microaggregate filter (provided), withdraw dose into syringe; discard filter<\/li><li>Benefix(R), administer by slow infusion over several minutes<\/li><li>Ixinity(R), connect prefilled syringe to vial adaptor (leave in plastic package) and screw until secured; remove syringe and vial adaptor from plastic package and place over the Ixinity(R) vial in a continuous motion; press down until the vial adaptor filter spike punctures the Ixinity(R) vial and the cap snaps on; transfer liquid from syringe into vial<\/li><li>Ixinity(R), gently swirl (with syringe and vial still attached) until product is fully reconstituted<\/li><li>Ixinity(R), remove prefilled syringe from the vial adaptor and attach administration syringe (provided); withdraw the solution from the vial through the filter spike, then unscrew the syringe<\/li><li>Ixinity(R), administration syringe (provided) may be used to pool up to 3 vials; if more than 3 vials are required, use a larger syringe (not provided)<\/li><li>Ixinity(R), administer reconstituted solution immediately (solution should be clear and colorless without visible particles) via IV infusion or within 3 hours of storage at room temperature; do not refrigerate<\/li><li>Ixinity(R), infuse at a rate comfortable to the patient, not to exceed 10 mL\/minute; do not mix with other products<\/li><li>Rixubis(TM), use the double-ended mixing device (provided) to puncture the single-dose diluent vial (provided) then invert and puncture the medication vial; allow the diluent to flow into the powder; swirl connected vials to mix; do not shake<\/li><li>Rixubis(TM), remove blue cap from the mixing device and attach syringe; turn the vials so medication is on top; draw solution into syringe and disconnect from the vials<\/li><li>Rixubis(TM), if using more than 1 vial, may combine contents of multiple vials in same syringe after reconstitution<\/li><li>Rixubis(TM), do not refrigerate after reconstitution; use within 3 hours; discard unused portion<\/li><li>Rixubis(TM), attach winged (butterfly) infusion set to syringe; administer by slow infusion, MAX 10 mL\/min<\/li><\/ul>"},"10":{"id":"928514-s-10","title":"Monitoring","mono":"<ul><li>normalization of coagulation parameters indicates efficacy<\/li><li>(Benefix(R)) factor IX assays prior to infusion; in patients with severe hemorrhage or undergoing major surgery<\/li><li>(Rixubis(TM) factor IX activity plasma levels to ensure desired effect<\/li><li>(Benefix(R)) early signs and symptoms of hypersensitivity reactions; especially in patients with major deletion mutations in the factor IX gene, rate of administration may need to be adjusted and\/or therapy discontinued<\/li><li>early signs of thrombotic or consumptive coagulopathy; especially in peri- or post operative patients, those with liver disease, those with signs of fibrinolysis, those with a predisposing risk of thrombotic events or disseminated intravascular coagulation, and in neonates<\/li><li>factor IX inhibitors; regularly via clinical observation or laboratory tests, and in patients with inadequate factor IX activity plasma levels or bleeding that is not controlled by the recommended dose<\/li><\/ul>"},"11":{"id":"928514-s-11","title":"How Supplied","mono":"<ul><li><b>BeneFIX<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/><\/li><li><b>Ixinity<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/><\/li><li><b>Rixubis<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/><\/li><\/ul>"},"13":{"id":"928514-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause dysgeusia or extremity pain.<\/li><li>Advise patient to report any adverse effects, including hypersensitivity reactions, following administration. Discontinue use if symptoms of hypersensitivity occur.<\/li><li>Counsel patient to report a lack of clinical response.<\/li><li>Tell patient about proper preparation and administration technique.<\/li><\/ul>"}}}